Anti-IDO1 antibody

Anti-IDO1 antibody

• DataSheet
• Material Safety Data Sheets (MSDS)

Rabbit Polyclonal to Human IDO1

ELISA, ICC/IF, IF

Human IDO1 / Indoleamine 2,3-dioxygenase

Indoleamine 2 antibody; 3‑dioxygenase antibody; IDO-1 antibody; Ido antibody; IDO antibody; Ido1 antibody; IDO1 antibody; Indo antibody; INDO antibody

Rabbit IgG

Produced in rabbits immunized with purified, recombinant Human IDO1 / Indoleamine 2,3-dioxygenase . IDO1 / Indoleamine 2,3-dioxygenase specific IgG was purified by Human IDO1 / Indoleamine 2,3-dioxygenase affinity chromatography.

Polyclonal

0.2 μm filtered solution in PBS

This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

Indoleamine 2,3-dioxygenase-1, also known as Indoleamine-pyrrole 2,3-dioxygenase, IDO1 and IDO, is a member of the indoleamine 2,3-dioxygenase family. IDO1 / IDO and tryptophan 2,3-dioxygenase (TDO) are tryptophan-degrading enzymes that catalyze the first step in tryptophan catabolism via the kynurenine pathway. TDO is widely distributed in both eukaryotes and bacteria. In contrast, IDO has been found only in mammals and yeast. In 2007, a third enzyme, indoleamine 2,3-dioxygenase-2 (IDO2), was discovered. IDO2 is found not only in mammals but also in lower vertebrates. IDO1 / IDO is an immunosuppressive molecule inducible in various cells. IDO1 / IDO catalyzes the cleavage of the pyrrol ring of tryptophan and incorporates both atoms of a molecule of oxygen. It mediates oxidative cleavage of tryptophan, an amino acid essential for cell proliferation and survival. IDO1 / IDO inhibition is proposed to have therapeutic potential in immunodeficiency-associated abnormalities, including cancer. The IDO pathway is activated in multiple tumor types. Selective inhibition of IDO1 may represent an attractive cancer therapeutic strategy via up-regulation of cellular immunity. IDO1 / IDO is an enzyme that suppresses adaptive T-cell immunity by catabolizing tryptophan from the cellular microenvironment. Inhibition of IDO pathway might enhance the efficacy of immunotherapeutic strategies for cancer.

Immune Checkpoint
Immune Checkpoint Detection: ELISA Antibodies
Co-inhibitory Immune Checkpoint Targets

Immunotherapy   Cancer Immunotherapy   Targeted Therapy